XML 30 R11.htm IDEA: XBRL DOCUMENT v3.24.1
Accounts Receivable
 12 Months Ended
Dec. 31, 2023
Receivables [Abstract]  
Accounts Receivable Accounts Receivable
The Company’s accounts receivable consists primarily of amounts due from third-party payors and patients. See Note 2 for a summary of the Company’s policies relating to accounts receivable and allowance for credit losses.
Accounts Receivable as of December 31, 2023 and December 31, 2022 consist of the following:
(in thousands)December 31, 2023December 31, 2022
Oral drug accounts receivable (Dispensary)$2,914 $4,165 
Capitated accounts receivable (Patient Services)1,757 1,623
FFS accounts receivable (Patient Services)30,173 26,313
Clinical trials accounts receivable2,595 2,443
Other trade receivables4,921 5,272
Total$42,360 $39,816 
The Company adopted ASU 2016-13, as amended, effective January 1, 2023, and determined no allowance for credit losses was required as of that date. No allowance for credit losses was recorded as of December 31, 2023.
No allowance for doubtful accounts was recorded as of December 31, 2022.
As of January 1, 2022, the accounts receivable balance amounted to $20,007.
During the years ended December 31, 2023 and 2022, the Company had net bad debt recoveries of $11, and bad debt recoveries of $169, respectively, and bad debt expense of $2,031 and $307, respectively. Bad debt write-offs were a result of accounts receivable on completed contracts that were deemed uncollectible during the period due to delayed collection efforts.